Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673161 | 1.00 | KIF11 (0.50) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL2327183 | 0.87 | ALPI (0.39) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL21367554 | 0.87 | ALPI (0.39) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL22922246 | 0.83 | MMP13 (0.39) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL17874881 | 0.83 | KIF11 (0.41) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL17874627 | 0.82 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL342512 | 0.81 | MAOA (0.57) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL1157625 | 0.81 | MAOA (0.57) | KIF11ALPIPKMPTGS1XIAP | |
| Cystine SCHEMBL27694930 | 0.81 | KIF11 (0.61) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL6223407 | 0.81 | MAOA (0.57) | KIF11ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252596-B1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UNIV MARQUETTE (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2252596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | Marquette University (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
| WO-2009100431-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100431-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | KIF11 4584/4885ALPI 4737/4885PKM 2360/4885 |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | KIF11 4584/4885ALPI 4737/4885PKM 2360/4885 |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | SLC7A11, CBS, CTH | KIF11 4330/4885ALPI 4863/4885PKM 1634/4885 |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | CTH, CBS, SLC6A3 | KIF11 4498/4885ALPI 4650/4885PKM 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.